Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...
However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...
The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...
The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to ...
A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...
Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...
Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...
Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...
In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...
George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...
Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by ...
The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results